Advertisement
Advertisement
MYGN
Myriad Genetics Inc
4.29
USDSponsored
+0.20
+4.89%
May 08, 16:00 UTC -4
Closed
After-Market
4.33
+0.04
+1.05%
MYGN Earnings Reports
Positive Surprise Ratio
MYGN beat 18 of 22 last estimates.
82%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$219.36M
/$0.01
Implied change from Q1 26 (Revenue/ EPS)
+9.46%
/-111.11%
Implied change from Q2 25 (Revenue/ EPS)
+2.94%
/-80.00%
Myriad Genetics Inc earnings per share and revenue
On May 05, 2026, MYGN reported earnings of -0.09 USD per share (EPS) for Q1 26, missing the estimate of -0.06 USD, resulting in a -28.94% surprise. Revenue reached 200.40 million, compared to an expected 206.53 million, with a -2.97% difference. The market reacted with a -18.29% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of 0.01 USD, with revenue projected to reach 219.36 million USD, implying an decrease of -111.11% EPS, and increase of 9.46% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Iovance Biotherapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.19
Surprise
-24.35%
Corvus Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.15
Surprise
-2.95%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
Ginkgo Bioworks Holdings, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.09
Actual
-$1.28
Surprise
-17.35%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Codexis, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+28.26%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
PTC Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.47
Actual
-$0.03
Surprise
+93.75%
Scholar Rock Holding Corporation Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.81
Actual
-$0.83
Surprise
-1.62%
FAQ
What were Myriad Genetics Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Myriad Genetics Inc reported EPS of -$0.09, missing estimates by -28.94%, and revenue of $200.40M, -2.97% below expectations.
How did the market react to Myriad Genetics Inc's Q1 2026 earnings?
The stock price moved down -18.29%, changed from $5.03 before the earnings release to $4.11 the day after.
When is Myriad Genetics Inc expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Myriad Genetics Inc's next earnings report?
Based on --
analysts, Myriad Genetics Inc is expected to report EPS of $0.01 and revenue of $219.36M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement